AbelZeta to Present Innovative Biopharmaceutical Research at LUPUS 2025 Congress

AbelZeta's Attendance at LUPUS 2025: A Promising Step in Autoimmune Disease Treatment



AbelZeta Pharma, Inc., a clinical-stage biopharmaceutical innovator, has announced its participation in the upcoming LUPUS 2025 conference, which is set to take place from May 21-24, 2025, in Toronto, Canada. During this prestigious event, AbelZeta will present findings related to its pioneering product, C-CAR168, a therapy aimed at tackling autoimmune and neurological disorders, including refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE).

Overview of C-CAR168


C-CAR168 is an autologous bi-specific CAR-T therapy that uniquely targets CD20 and B-cell maturation antigens (BCMA). This innovative approach positions C-CAR168 as a potential game changer in treating some of the most challenging autoimmune diseases. Notably, the U.S. Food and Drug Administration (FDA) has already cleared AbelZeta to proceed with a Phase 1 clinical study of this therapy, showcasing its promise in medical applications.

The preclinical data obtained from previous studies on C-CAR168 were initially showcased during the American College of Rheumatology (ACR) Convergence 2024, which further underscores its potential and the interest it has generated within the medical community.

Details of the LUPUS 2025 Presentation


The upcoming conference will feature an oral presentation of AbelZeta's findings:
  • - Abstract Title: Clinical Impact of C-CAR168, A Novel Anti-CD20/BCMA Composite Autologous CAR-T Therapy, in Refractory Lupus Nephritis
  • - Session Title: Abstract Concurrent Session 04 Advancing Lupus Therapies and Insights
  • - Presentation Time: May 22, 2025, from 14:10 to 14:20
  • - Presenter: Dr. Nan Shen, M.D., PhD, Principal Investigator at AbelZeta
  • - Location: Westin Harbour Castle, Toronto, Ontario, Canada, Room Queens Quay

In addition to this crucial presentation, Barbara Mittleman, M.D., the Vice President of Clinical Development at AbelZeta, has been invited to speak in a scientific session titled “Cell Therapy in Lupus” on May 23, 2025. This session will delve into the current landscape of cell therapy in SLE, discussing both advancements and the challenges that remain.

AbelZeta's Vision


As a clinical-stage biopharmaceutical company with operations in Rockville, Maryland, and Shanghai, China, AbelZeta Pharma is dedicated to advancing innovative therapies that leverage the body’s immune response to combat various medical conditions. The firm focuses on developing proprietary cell-based treatments, particularly in the fields of oncology and immunological diseases.

This commitment to pioneering research and development not only illustrates AbelZeta's ambition to combat significant health challenges but also highlights its strategic position within the biopharmaceutical landscape. The company aims to bring transformative therapies to market that could greatly improve patient lives and health outcomes.

Conclusion


The participation of AbelZeta at LUPUS 2025 signifies a notable milestone in the ongoing quest for effective treatments in the realm of autoimmune diseases. The innovations presented, such as C-CAR168, hold great promise and could pave the way for new hope for patients battling these challenging conditions. As the conference approaches, industry experts and participants gather to witness the evolution of therapeutic solutions and engage in pivotal discussions shaping the future of lupus treatment.

For more information on C-CAR168 and other AbelZeta initiatives, interested parties can visit AbelZeta's website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.